Anti-MAP3K14 Polyclonal Antibody

Anti-MAP3K14 Polyclonal Antibody is a Rabbit antibody targeting MAP3K14. Anti-MAP3K14 Polyclonal Antibody can be used in FCM,IF,IHC-Fr,IHC-P,WB.

IgG

Human,Mouse (predicted:Rat,Dog,Cow,Horse,Rabbit)

1. Sample:
Kidney (Mouse) lysate at 30 μg;
Brain (Mouse) lysate at 30 μg
Primary: Anti-NFkB Inducing Kinase NIK (TMAB-01101) at 1:300 dilution;
Secondary: HRP conjugated Goat-Anti-Rabbit Igg (secondary antibody) at 1: 5000 dilution;
Predicted band size: 104 kDa
Observed band size: 104 kDa
2. Tissue/cell: human colon carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer (0.01M, pH6.0), Boiling bathing for 15 min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30 min; Blocking buffer (normal goat serum) at 37°C for 20 min;
Incubation: Anti-HSNIK Polyclonal Antibody, Unconjugated (TMAB-01101) 1:500, overnight at 4°C, followed by conjugation to the secondary antibody and DAb staining.
3. Blank control: A431. Primary Antibody (green line): Rabbit Anti-NFkB Inducing Kinase NIK antibody (TMAB-01101)
Dilution: 1 μg/10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG.
Secondary Antibody: Goat anti-rabbit IgG-AF647
Dilution: 1 μg/test.
Protocol
The cells were fixed with 4% PFA (10 min at room temperature) and then permeabilized with 0.1% PBST for 20 min at room temperature. The cells were then incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature.

WB: 1:500-2000; IHC-P: 1:100-500; IHC-Fr: 1:100-500; IF: 1:100-500; FCM: 3ug/Test

Polyclonal

KLH conjugated synthetic peptide: human NIK

Human

MAP3K14

Mitogen-activated protein kinase kinase kinase 14

Kinases,NFkB pathway,Other Kinases,NFkB Pathway

Lymphotoxin beta-activated kinase which seems to be exclusively involved in the activation of NF-kappa-B and its transcriptional activity. Promotes proteolytic processing of NFKB2/P100, which leads to activation of NF-kappa-B via the non-canonical pathway. Could act in a receptor-selective manner.